NEWS
< back to news list

NanoGroup acquired shares of Medinice S.A.

NanoGroup S.A. announced the acquisition of 162,500 shares of the technology company Medinice S.A. at a price of PLN 8 per share, which in total constitutes an investment worth PLN 1.3 million. The transaction was announced on October 16, 2024 and was executed on the Warsaw Stock Exchange as part of a block transaction, outside the quotation system.

At the same time, NanoGroup has entered into an agreement with eCapital, which assumes the possibility of reselling the acquired shares at a price not lower than the purchase price. The agreement gives NanoGroup complete security of the transaction, causing it to have no financial risk related to the possibility of losing financial resources, while allowing it to consume the potential successes of Medinice. The agreement was concluded on October 16 this year and is valid for a year.

Medinice S.A. is a Polish company founded in 2012, specializing in the creation and commercialization of innovative, minimally invasive medical solutions, especially in the fields of cardiology and cardiac surgery. The company’s portfolio currently includes several projects with global potential, at various stages of development. Medinice is approaching the certification of the first projects and potential partnering transactions.

The unique nature of the transaction

It is worth emphasizing that this transaction is of an exceptional nature and constitutes a purely financial action, which was possible only thanks to the appropriate security of the investor. NanoGroup does not plan to carry out similar actions in the future, as the company focuses on its core business, i.e. research and development works and the implementation of key projects, such as the NanOX system.

NanoGroup remains focused on its innovative biotechnology and nanotechnology businesses and the Medinice transaction is a one-time, risk-free transaction that does not distract from the company’s core projects.

Copyright © NanoGroup 2024

Prof. Tomasz Ciach

Founder, Member of the Management Board of NANOGROUP S.A.

Nanotechnology expert. Professor at the Faculty of Chemical and Processing Engineering, Warsaw University of Technology, head of the Biotechnology and Bioprocessing Division. Author of two technologies that are already in production stage, 12 granted patents and over 50 publications. Founder of BioMedLab research group, consultant in numerous companies (AstraZeneca, Procter and Gamble, Reckit, Adamed, Balton, Galmed). Work on various aspects of Biomedical Engineering, mostly on biomedical nanotechnology, active coatings for medical implants, nanoparticles for cancer treatment, biodegradable and nonbiodegradable implants, bone and vascular prosthesis. He gives rare, but already brilliant example of how brave ideas become socially and financially valuable.

Piotr Mierzejewski

Vice President of the Management Board of NANOGROUP S.A.

Clinical pharmacology specialist, former advisor to the Minister of Health on drug policy. He negotiated Poland’s accession to the EU in the field of pharmacy, responsible for the implementation of EU directives in the field of pharmacy into the Polish legal system. Co-founder of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Owner of a consulting company cooperating with international pharmaceutical companies in the field of introducing new technologies to the Polish market.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.